Galactomannan, a Surrogate Marker for Outcome in Invasive Aspergillosis: Finally Coming of Age
Detection of galactomannan has become widely available for diagnosing invasive aspergillosis. The test characteristics, using the Platelia™ enzyme-immunoassay, have been well described. This assay could potentially also be useful for the early evaluation of the efficacy of antifungal therapy and for...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2018-04-01
|
| Series: | Frontiers in Microbiology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/article/10.3389/fmicb.2018.00661/full |
| _version_ | 1818608050466979840 |
|---|---|
| author | Toine Mercier Toine Mercier Ellen Guldentops Katrien Lagrou Katrien Lagrou Johan Maertens Johan Maertens |
| author_facet | Toine Mercier Toine Mercier Ellen Guldentops Katrien Lagrou Katrien Lagrou Johan Maertens Johan Maertens |
| author_sort | Toine Mercier |
| collection | DOAJ |
| description | Detection of galactomannan has become widely available for diagnosing invasive aspergillosis. The test characteristics, using the Platelia™ enzyme-immunoassay, have been well described. This assay could potentially also be useful for the early evaluation of the efficacy of antifungal therapy and for predicting the outcome in terms of response and survival. In this systematic review, we assessed the available evidence for the use of serum galactomannan at baseline as a prognostic marker, and the predictive value of serum galactomannan kinetics after initiation of antifungal therapy. Overall, serum galactomannan at baseline and galactomannan kinetics appear to be good predictors of therapy response and survival. However, breakpoints for predicting therapy failure and validation in different patient populations are still lacking. |
| first_indexed | 2024-12-16T14:36:29Z |
| format | Article |
| id | doaj.art-aa342fee2e90470ca30e7b6c984f22ca |
| institution | Directory Open Access Journal |
| issn | 1664-302X |
| language | English |
| last_indexed | 2024-12-16T14:36:29Z |
| publishDate | 2018-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Microbiology |
| spelling | doaj.art-aa342fee2e90470ca30e7b6c984f22ca2022-12-21T22:28:04ZengFrontiers Media S.A.Frontiers in Microbiology1664-302X2018-04-01910.3389/fmicb.2018.00661356760Galactomannan, a Surrogate Marker for Outcome in Invasive Aspergillosis: Finally Coming of AgeToine Mercier0Toine Mercier1Ellen Guldentops2Katrien Lagrou3Katrien Lagrou4Johan Maertens5Johan Maertens6Laboratory of Clinical Bacteriology and Mycology, Department of Microbiology and Immunology, KU Leuven, Leuven, BelgiumDepartment of Hematology, University Hospitals Leuven, Leuven, BelgiumDepartment of Hematology, University Hospitals Leuven, Leuven, BelgiumLaboratory of Clinical Bacteriology and Mycology, Department of Microbiology and Immunology, KU Leuven, Leuven, BelgiumDepartment of Laboratory Medicine and National Reference Center for Mycosis, University Hospitals Leuven, Leuven, BelgiumLaboratory of Clinical Bacteriology and Mycology, Department of Microbiology and Immunology, KU Leuven, Leuven, BelgiumDepartment of Hematology, University Hospitals Leuven, Leuven, BelgiumDetection of galactomannan has become widely available for diagnosing invasive aspergillosis. The test characteristics, using the Platelia™ enzyme-immunoassay, have been well described. This assay could potentially also be useful for the early evaluation of the efficacy of antifungal therapy and for predicting the outcome in terms of response and survival. In this systematic review, we assessed the available evidence for the use of serum galactomannan at baseline as a prognostic marker, and the predictive value of serum galactomannan kinetics after initiation of antifungal therapy. Overall, serum galactomannan at baseline and galactomannan kinetics appear to be good predictors of therapy response and survival. However, breakpoints for predicting therapy failure and validation in different patient populations are still lacking.http://journal.frontiersin.org/article/10.3389/fmicb.2018.00661/fullgalactomannankineticsinvasive aspergillosisprognosisoutcome |
| spellingShingle | Toine Mercier Toine Mercier Ellen Guldentops Katrien Lagrou Katrien Lagrou Johan Maertens Johan Maertens Galactomannan, a Surrogate Marker for Outcome in Invasive Aspergillosis: Finally Coming of Age Frontiers in Microbiology galactomannan kinetics invasive aspergillosis prognosis outcome |
| title | Galactomannan, a Surrogate Marker for Outcome in Invasive Aspergillosis: Finally Coming of Age |
| title_full | Galactomannan, a Surrogate Marker for Outcome in Invasive Aspergillosis: Finally Coming of Age |
| title_fullStr | Galactomannan, a Surrogate Marker for Outcome in Invasive Aspergillosis: Finally Coming of Age |
| title_full_unstemmed | Galactomannan, a Surrogate Marker for Outcome in Invasive Aspergillosis: Finally Coming of Age |
| title_short | Galactomannan, a Surrogate Marker for Outcome in Invasive Aspergillosis: Finally Coming of Age |
| title_sort | galactomannan a surrogate marker for outcome in invasive aspergillosis finally coming of age |
| topic | galactomannan kinetics invasive aspergillosis prognosis outcome |
| url | http://journal.frontiersin.org/article/10.3389/fmicb.2018.00661/full |
| work_keys_str_mv | AT toinemercier galactomannanasurrogatemarkerforoutcomeininvasiveaspergillosisfinallycomingofage AT toinemercier galactomannanasurrogatemarkerforoutcomeininvasiveaspergillosisfinallycomingofage AT ellenguldentops galactomannanasurrogatemarkerforoutcomeininvasiveaspergillosisfinallycomingofage AT katrienlagrou galactomannanasurrogatemarkerforoutcomeininvasiveaspergillosisfinallycomingofage AT katrienlagrou galactomannanasurrogatemarkerforoutcomeininvasiveaspergillosisfinallycomingofage AT johanmaertens galactomannanasurrogatemarkerforoutcomeininvasiveaspergillosisfinallycomingofage AT johanmaertens galactomannanasurrogatemarkerforoutcomeininvasiveaspergillosisfinallycomingofage |